NASDAQ: MOTSMotus Gi Holdings Inc Stock
$0.73+0.01 (+1.39%)
Updated May 26, 2023
MOTS Price
$0.73
Fair Value Price
$5.06
Market Cap
$3.49M
52 Week Low
$0.62
52 Week High
$6.30
P/E
-0.15x
P/B
-3.22x
P/S
7.38x
PEG
N/A
Dividend Yield
N/A
Revenue
$628.00k
Earnings
-$18.17M
Gross Margin
-26.8%
Operating Margin
-2,709.08%
Profit Margin
-2,893.6%
Debt to Equity
-12.27
Operating Cash Flow
-$17M
Beta
0.84
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
MOTS Overview
Motus GI Holdings, Inc., a medical technology company, develops Pure-Vu system, a medical device to facilitate the cleaning of a poorly prepared gastrointestinal tract during the colonoscopy and facilitates upper gastrointestinal endoscopy procedure. The company was incorporated in 2016 and is based in Fort Lauderdale, Florida.
Zen Score
–
Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how MOTS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MOTS ($0.73) is undervalued by 85.56% relative to our estimate of its Fair Value price of $5.06 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
MOTS ($0.73) is significantly undervalued by 85.56% relative to our estimate of its Fair Value price of $5.06 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
MOTS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more MOTS due diligence checks available for Premium users.
Be the first to know about important MOTS news, forecast changes, insider trades & much more!
MOTS News
Valuation
MOTS fair value
Fair Value of MOTS stock based on Discounted Cash Flow (DCF)
Price
$0.73
Fair Value
$5.06
Undervalued by
85.56%
MOTS ($0.73) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
MOTS ($0.73) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
MOTS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
MOTS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.15x
Industry
30.3x
Market
54.23x
MOTS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-3.22x
Industry
3.97x
MOTS's financial health
Profit margin
Revenue
$56.0k
Net Income
-$4.4M
Profit Margin
-7,832.1%
MOTS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
MOTS's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$12.2M
Liabilities
$13.3M
Debt to equity
-12.27
MOTS's short-term assets ($10.26M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MOTS's short-term assets ($10.26M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MOTS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
MOTS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.8M
Investing
-$39.0k
Financing
-$553.0k
MOTS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MOTS vs Diagnostic & Research Stocks
Motus Gi Holdings Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.